1. Home
  2. REBN vs JSPR Comparison

REBN vs JSPR Comparison

Compare REBN & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reborn Coffee Inc.

REBN

Reborn Coffee Inc.

HOLD

Current Price

$1.53

Market Cap

13.2M

ML Signal

HOLD

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$0.49

Market Cap

14.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REBN
JSPR
Founded
2015
2018
Country
United States
United States
Employees
N/A
22
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
14.9M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
REBN
JSPR
Price
$1.53
$0.49
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$15.50
AVG Volume (30 Days)
46.8K
705.5K
Earning Date
04-22-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,094,628.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
36.54
N/A
52 Week Low
$1.36
$0.42
52 Week High
$3.40
$7.19

Technical Indicators

Market Signals
Indicator
REBN
JSPR
Relative Strength Index (RSI) 37.53 34.19
Support Level $1.39 $0.42
Resistance Level $2.00 $1.02
Average True Range (ATR) 0.17 0.07
MACD 0.01 0.01
Stochastic Oscillator 27.50 25.07

Price Performance

Historical Comparison
REBN
JSPR

About REBN Reborn Coffee Inc.

Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is a company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in two reportable segments: Reborn Coffee, which includes both the wholesale and retail sales of coffee, water, and other beverages, and Reborn Logistics, which provides freight forwarding services.

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Share on Social Networks: